Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEX168 vs placebo in type 2 diabetes mellitus
CTR20140233Phase 3Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Jul 2015
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of polyethylene glycol loxenatide in type 2 diabetes mellitus (T2DM), sponsored by Hengrui Therapeutics. Started Jul 2015; status: completed.
02
Drugs
polyethylene glycol loxenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20140233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140233.